Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients

Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients

Abstract Background Coronavirus SARS-CoV-2, the causative agent of COVID-19, has caused a still evolving global pandemic. Given the worldwide vaccination campaign, the understanding of the vaccine-induced versus COVID-19-induced immunity will contribute to adjusting vaccine dosing strategies and spe...

Full description

Bibliographic Details
Main Authors: Ioannis P. Trougakos, Evangelos Terpos, Christina Zirou, Aimilia D. Sklirou, Filia Apostolakou, Sentiljana Gumeni, Ioanna Charitaki, Eleni-Dimitra Papanagnou, Tina Bagratuni, Christine-Ivy Liacos, Andreas Scorilas, Eleni Korompoki, Ioannis Papassotiriou, Efstathios Kastritis, Meletios A. Dimopoulos
Format: Article
Language:English
Published: BMC 2021-08-01
Series:BMC Medicine
Subjects:
Anti-S-RBD IgGs
BNT162b2 vaccine
COVID-19
Neutralizing antibodies
SARS-CoV-2
Viral infection
Online Access:https://doi.org/10.1186/s12916-021-02090-6

Internet

https://doi.org/10.1186/s12916-021-02090-6

Similar Items